Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025)
Candel Therapeutics' (CADL) quarterly Return on Capital Employed came in at 48.07% in Q4 2025, up 7709.0% year-on-year from 0.62% in Q4 2024, and down 5.07% quarter-over-quarter from 45.75% in Q3 2025.
Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025) Analysis & Trends
Candel Therapeutics has disclosed Return on Capital Employed across 5 years of filings, most recently posting 48.07% for Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 48.07%, up 7709.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 48.07% (up 7709.0% YoY), and the FY2025 annual result was 45.09%, up 4632.0% from the prior year.
- Return on Capital Employed came in at 48.07% for Q4 2025 at Candel Therapeutics, down from 45.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.5% in Q4 2021 to a low of 407.05% in Q3 2024.
- The 5-year median for Return on Capital Employed is 46.96% (2025), against an average of 92.3%.
- Across the five-year window, Return on Capital Employed tumbled 32495 bps in 2024 and soared 36130 bps in 2025, its largest moves.
- Candel Therapeutics' Return on Capital Employed stood at 29.5% in 2021, then sank by 55 bps to 45.85% in 2022, then tumbled by 166 bps to 122.08% in 2023, then retreated by 3 bps to 125.16% in 2024, then surged by 62 bps to 48.07% in 2025.
- The last three Return on Capital Employed figures came in at 48.07% (Q4 2025), 45.75% (Q3 2025), and 41.99% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | -48.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -48.07% |
| Sep 30, 2025 | -45.75% |
| Jun 30, 2025 | -41.99% |
| Mar 31, 2025 | -41.32% |
| Dec 31, 2024 | -125.16% |
| Sep 30, 2024 | -407.05% |
| Jun 30, 2024 | -240.00% |
| Mar 31, 2024 | -161.70% |
| Dec 31, 2023 | -122.08% |
| Sep 30, 2023 | -82.11% |
| Jun 30, 2023 | -66.04% |
| Mar 31, 2023 | -52.61% |
| Dec 31, 2022 | -45.85% |
| Sep 30, 2022 | -41.27% |
| Jun 30, 2022 | -36.60% |
| Mar 31, 2022 | -33.43% |
| Dec 31, 2021 | -29.50% |
| Sep 30, 2021 | -40.90% |